Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Guangdong Taiantang Pharmaceutical Co Ltd Announces FY 2012 Net Profit Outlook, In Line With I/B/E/S Estimates


Monday, 22 Oct 2012 08:00pm EDT 

Guangdong Taiantang Pharmaceutical Co Ltd announced that it expects its net profit for fiscal year (FY) 2012 to be RMB 815,678,771,400 - 1,038,136,618,100 (or to increase by 10% - 40%), compared to the net profit of FY 2011 (RMB 74,152,615.58). The Company cited the increased sales as the main reason for the forecast. According to I/B/E/S Estimates, analysts were expecting the Company to report net profit of RMB 103.13 million for the fiscal year 2012. 

Company Quote